Inaqovi (Decitabine, Cedazuridine)

Decitabine integrates into DNA and blocks DNA methyltransferase, leading to hypomethylation and re‑activation of silenced genes that control cell growth. Cedazuridine inhibits the enzyme cytidine deaminase, which normally degrades decitabine, thereby increasing the drug’s oral bioavailability and allowing effective systemic exposure from a tablet.

The specific dose and dosing schedule of Inaqovi are determined by the prescribing clinician based on the patient’s disease characteristics, renal and hepatic function, and overall health status. Healthcare professionals should follow the approved prescribing information and adjust as needed.

The safety of Inaqovi in pregnancy or while breastfeeding has not been established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant. Women of childbearing potential should use effective contraception during treatment and for a period after the last dose.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Inaqovi combines decitabine with cedazuridine to enable oral administration, whereas traditional hypomethylating agents such as decitabine alone require intravenous infusion. The oral formulation offers greater convenience and may improve patient adherence while delivering comparable pharmacologic exposure when taken as prescribed.

Inaqovi tablets should be stored at ambient temperature, below 25 °C. Keep them in the original blister pack, protect from moisture, heat and direct sunlight, and keep out of reach of children.

Inaqovi is taken orally, usually once daily on a scheduled treatment cycle as defined by the prescriber. The tablets should be swallowed whole with water and not crushed or chewed, unless otherwise directed by a healthcare professional.

The most serious risks include severe myelosuppression leading to infections, bleeding, or anemia; life‑threatening infections due to neutropenia; pulmonary toxicity such as interstitial pneumonitis; and rare severe skin reactions like Stevens‑Johnson syndrome. Patients should be monitored closely for these events.

Inaqovi is contraindicated in patients with known hypersensitivity to decitabine, cedazuridine, or any tablet excipients. It should also be avoided in individuals with uncontrolled infections, severe hepatic impairment, or those receiving live vaccines without appropriate clinical justification.